m+Medelevator.RU
← Поиск публикаций
Journal of controlled release : official journal of the Controlled Release Society · 2026

Nanotechnology-based strategies for ROS-mediated anticancer and antimicrobial therapies.

СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Pechnikova Nadezhda A, Poimenidou Malamati, Lam Myra, Aleksandrova Mariia V, Ostankova Yulia V, Aggeli Amalia, Yaremenko Alexey V

Аннотация

Reactive oxygen species (ROS) are chemically reactive oxygen derivatives which are capable of profoundly altering cellular pathways. Due to their ability to induce oxidative damage and damage cells, ROS have been explored as a promising avenue to combat cancer and treat pathogenic bacteria. Recent intersections in the development of nanotechnology and ROS-based therapeutics include engineered nanoparticles, enzyme-mimicking nanozymes, and metal-organic frameworks. These nanoplatforms allow refined control of spatiotemporal generation of ROS within desired tissue, improved ROS targeting of cancer lesions and at sites of bacterial infection, and concurrent delivery of ROS-incorporated, multi-therapeutic agents. In this review, we outline the fundamental principles and advancements of ROS-based nanotherapies that have been used against both malignant cells and pathogenic bacteria, including photodynamic, sonodynamic, chemodynamic, and radiotherapeutic approaches. In addition, we explore strategies that combine ROS with immunotherapy or antibiotics to elicit synergistic anti-cancer or antimicrobial effects. Although ROS-based therapies face challenges in the current landscape, including limited tissue penetration, toxicity, and difficulties with in vivo monitoring, there are ongoing efforts to address these hurdles. Once a better mechanistic understanding of ROS is established and key biosafety criteria are met, once these challenges are addressed, ROS-based nanotherapies can serve as a powerful tool against tumors and drug-resistant bacteria, enable more effective personalized treatments, and advance precision medicine.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты